Key clinical point: No anti-inflammatory or clinical effects occurred with lovastatin in adults with rheumatoid arthritis (RA) after 12 weeks of treatment, compared with placebo, but lovastatin was associated with reduced C-reactive protein (CRP) in patients not using biologics.
Major finding: No significant difference in CRP levels occurred among lovastatin patients compared with placebo patients, however, significantly more adults with RA in the lovastatin group who were not on biologics achieved a reduction of 20% or higher in CRP levels from baseline, compared with placebo patients (P = 0.007).
Study details: A randomized, double-blind trial of 64 patients with mild RA and elevated CRP levels.
Disclosures: The researchers had no financial conflicts to disclose. The study was funded by the Autoimmunity Centers of Excellence. Lovastatin and placebo were provided by Teva Pharmaceutical Industries, but the company had no other role in the study.
Aranow C et al. Rheumatology. 2019 Oct 18. doi: 10.1093/rheumatology/kez471.